drugset / Trial / NCT00645320

A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study

NCT00645320

Phase 4 Completed 75 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and tolerability of ziprasidone in patients who successfully completed a study of ziprasidone treatment of psychosis (Protocol A1281074).

Timeline

Start
2003-08
Primary completion
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziprasidone Small molecule 40 mg Oral
Subject Ziprasidone Small molecule 80 mg Oral

Indications